Robin AI Identifies 2 dAMD Drug Candidates, Uncovering ABCA1 Target
Updated
Updated · Nature.com · May 19
Robin AI Identifies 2 dAMD Drug Candidates, Uncovering ABCA1 Target
2 articles · Updated · Nature.com · May 19
Nature published results showing Robin autonomously generated hypotheses, proposed experiments, analyzed data and validated two dry age-related macular degeneration candidates—ripasudil and KL001—in vitro.
Robin focused on boosting retinal pigment epithelium phagocytosis, then used a follow-up RNA-seq experiment to trace ripasudil’s effect to upregulation of ABCA1, a lipid efflux pump flagged as a possible new target.
Ripasudil is already a clinically used ROCK inhibitor, but the paper says it had not previously been proposed for dAMD, the leading cause of blindness in the developed world.
The authors describe Robin as the first multi-agent system to automate both hypothesis generation and data analysis in experimental biology, framing it as a semi-autonomous, lab-in-the-loop model for AI-driven discovery.
An AI found a glaucoma drug might treat blindness. How quickly could this discovery actually reach patients?
With AI now generating and validating hypotheses, what is the new role for human scientists in discovery?
AI learns from past successes. Can it generate disruptive ideas that challenge established scientific beliefs?
AI Breakthrough: Robin Identifies Ripasudil, KL001, and ABCA1 as Rapid dAMD Therapeutic Leads
Overview
On May 19, 2026, FutureHouse's multi-agent AI system, Robin, achieved a major breakthrough by rapidly identifying two promising drug candidates, Ripasudil and KL001, for dry age-related macular degeneration (dAMD). Robin's success comes from its integration of specialized AI agents—Crow, Falcon, and Owl for literature search, Phoenix for chemical synthesis, and Finch for data analysis—enabling full automation of complex discovery tasks. This approach allowed Robin to not only pinpoint potential drugs but also design and plan detailed RNA sequencing experiments, demonstrating how advanced AI can accelerate and deepen the drug discovery process.